Irreversible electroporation of hepatic malignancy

Seminars in Interventional Radiology

Volumn 30, Issue 1, 2013, Pages 67-73

  Narayanan, Govindarajan ^a   Froud, Tatiana ^a   Suthar, Rekhaben ^a   Barbery, Katuska ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

apoptosis; hepatocellular carcinoma (HCC) ablation; irreversible electroporation (IRE); NanoKnife

Indexed keywords

EID: 84874392759     PISSN: 07399529     EISSN: 10988963     Source Type: Journal    
DOI: 10.1055/s-0033-1333655     Document Type: Article

References (27)

1. Parkin D. M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J Clin: 2005; 55 2 74 108
2. Llovet J. M., Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol: 2008; 48 01 S20 S37
3. Bosch F. X., Ribes J., Díaz M., Cléries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology: 2004; 127 5 01 S5 S16
4. Seeff L. B. Introduction: the burden of hepatocellular carcinoma. Gastroenterology: 2004; 127 5 01 S1 S4
5. Davila J. A., Morgan R. O., Shaib Y., McGlynn K. A., El-Serag H. B. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology: 2004; 127 5 1372 1380
6. Davila J. A., Morgan R. O., Shaib Y., McGlynn K. A., El-Serag H. B. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut: 2005; 54 4 533 539
7. Llovet J. M., Ricci S., Mazzaferro V., et al. SHARP Investigators Study Group Sorafenib in advanced hepatocellular carcinoma. N Engl J Med: 2008; 359 4 378 390
8. Rodrguez de Lope C., Tremosini S., Forner A., et al. Management of HCC. J Hepatol: 2012; 56 6 1317 1323
9. Figueras J., Jaurrieta E., Valls C., et al. Resection or transplantation for hepatocellular carcinoma in cirrhotic patients: outcomes based on indicated treatment strategy. J Am Coll Surg: 2000; 190 5 580 587
10. Yao F. Y., Bass N. M., Nikolai B., et al. Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transpl: 2002; 8 10 873 883
11. Bruix J., Sherman M. Practice Guidelines Committee, American Association for the Study of Liver Diseases Management of hepatocellular carcinoma. Hepatology: 2005; 42 5 1208 1236
12. Cho Y. K., Kim J. K., Kim M. Y., Rhim H., Han J. K. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology: 2009; 49 2 453 459
13. Teratani T., Yoshida H., Shiina S., et al. Radiofrequency ablation for hepatocellular carcinoma in so-called high-risk locations. Hepatology: 2006; 43 5 1101 1108
14. Mahvi D. M., Lee F. T. Jr. Radiofrequency ablation of hepatic malignancies: is heat better than cold? Ann Surg: 1999; 230 1 9 11
15. Nahum Goldberg S., Dupuy D. E. Image-guided radiofrequency tumor ablation: challenges and opportunities-part I. J Vasc Interv Radiol: 2001; 12 9 1021 1032
16. Neumann E., Schaefer-Ridder M., Wang Y., Hofschneider P. H. Gene transfer into mouse lyoma cells by electroporation in high electric fields. EMBO J: 1982; 1 841 845
17. Okino M., Mohri H. Effects of a high-voltage electrical impulse and an anticancer drug on in vivo growing tumors. Jpn J Cancer Res: 1987; 78 12 1319 1321
18. Mir L. M., Orlowski S., Belehradek J. Jr, Paoletti C. Electrochemotherapy potentiation of antitumour effect of bleomycin by local electric pulses. Eur J Cancer: 1991; 27 1 68 72
19. Davalos R. V., Mir I. L., Rubinsky B. Tissue ablation with irreversible electroporation. Ann Biomed Eng: 2005; 33 2 223 231
20. Rubinsky B., Onik G., Mikus P. Irreversible electroporation: a new ablation modality-clinical implications. Technol Cancer Res Treat: 2007; 6 1 37 48
21. Lee E. W., Chen C., Prieto V. E., Dry S. M., Loh C. T., Kee S. T. Advanced hepatic ablation technique for creating complete cell death: irreversible electroporation. Radiology: 2010; 255 2 426 433
22. Thomson K. R., Cheung W., Ellis S. J., et al. Investigation of the safety of irreversible electroporation in humans. J Vasc Interv Radiol: 2011; 22 5 611 621
23. Narayanan G., Froud T., Lo K., Barbery K. J., Perez-Rojas E., Yrizarry J. Pain analysis in patients with hepatocellular carcinoma: irreversible electroporation versus radiofrequency ablation-initial observations. Cardiovasc Intervent Radiol: 2012;; June 30 (Epub ahead of print)
24. Kingham T. P., Karkar A. M., D'Angelica M. I., et al. Ablation of perivascular hepatic malignant tumors with irreversible electroporation. J Am Coll Surg: 2012; 215 3 379 387
25. Narayanan G., Hosein P., Arora G., Barbery K. J., Yrizarry J. Percutaneous irreversible electroporation (ire) in the treatment of HCC and metastatic colorectal cancer (MCRC) to the liver. J Vasc Interv Radiol: 2012; 23 12 1613 1621
26. El-Serag H. B. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology: 2004; 127 5 01 S27 S34
27. El-Serag H. B., Davila J. A., Petersen N. J., McGlynn K. A. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med: 2003; 139 10 817 823